GENELUX Corp (GNLX) - Dilution Analysis

10-Q filing | 44.2M shares outstanding

10-K filing | 44.8M shares outstanding

8-K filing: Genelux Corporation entered into an underwriting agreement to issue and sell 6,666,667 shares of common stock at $3.00 per share in an underwritten public offering, with gross proceeds of approximately $20.0 million before deducting underwriting discounts and commissions. ($20.0M proceeds)

10-Q filing | 37.9M shares outstanding

10-Q filing | 37.9M shares outstanding

10-Q filing | 34.9M shares outstanding

10-K filing | 31.5M shares outstanding

8-K filing: The Company entered into an underwriting agreement with Titan Partners Group to issue and sell 3,000,000 shares of common stock at $3.50 per share in an underwritten registered direct offering, with gross proceeds expected to be $10.5 million. ($10.5M proceeds)

10-Q filing | 34.5M shares outstanding

10-Q filing | 34.5M shares outstanding

8-K filing: The Underwriters exercised their option to purchase an additional 625,000 shares of the Company's common stock and accompanying warrants to purchase 625,000 shares of Common Stock at a combined offering price of $4.00 per share and accompanying Warrant, resulting in net proceeds to the Company of approximately $2.35 million. ($2.5M proceeds)

8-K filing: Genelux Corporation entered into an underwriting agreement to issue and sell 6,875,000 shares of common stock and accompanying warrants to purchase 6,875,000 shares of common stock at a combined offering price of $4.00 per share and warrant, with net proceeds expected to be approximately $25.4 million. ($27.5M proceeds)

10-Q filing | 26.8M shares outstanding

10-K filing | 24.4M shares outstanding

S-3 filing: The company may offer up to $300,000,000 of any combination of shares of its common stock, shares of its preferred stock, debt securities and warrants to purchase any of such securities.

10-Q filing | 26.2M shares outstanding

10-Q filing | 25.1M shares outstanding

S-1 filing: The filing relates to the potential resale from time to time of up to an aggregate of 1,315,213 shares of common stock by the selling stockholders.

8-K filing: Genelux Corporation entered into a Securities Purchase Agreement to sell and issue 900,000 shares of common stock at $20.00 per share in a private placement, expecting gross proceeds of approximately $18.0 million. ($18.0M proceeds)

10-Q filing | 24.7M shares outstanding

S-1/A filing: This is an S-1/A filing for an initial public offering of common stock. The underwriters may engage in activities that stabilize, maintain or otherwise affect the price of the shares of our common stock during and after this offering.

S-1/A filing: This is an S-1/A filing related to an initial public offering, with underwriters including The Benchmark Company and Brookline Capital Markets. The filing discusses lock-up agreements, Nasdaq listing requirements, stabilization activities, and underwriter warrants.

S-1/A filing: This is an S-1/A filing for an initial public offering of common stock, with The Benchmark Company and Brookline Capital Markets as underwriters. The filing includes information about lock-up agreements, stock exchange listing, and stabilization activities.

S-1/A filing: This S-1/A filing relates to a proposed offering of the company's common stock and includes information regarding underwriters, lock-up agreements, stock exchange listing, and stabilization activities.

S-1/A filing: This is an S-1/A filing for an offering of common stock underwritten by The Benchmark Company and Brookline Capital Markets. The company has applied to list its common stock on the Nasdaq Capital Market under the symbol "GNLX."

S-1/A filing: S-1/A filing for a common stock offering underwritten by The Benchmark Company and Brookline Capital Markets.

S-1 filing: This is an S-1 filing for an initial public offering of common stock underwritten by The Benchmark Company, Brookline Capital Markets, and Valuable Capital Limited. Warrants to purchase common stock will be issued to Benchmark.